Results 191 to 200 of about 104,116 (405)

STRUCTURE OF MORPHINE AND BUPRENORPHINE

, 1978
J.W. Downing
openalex   +1 more source

Buprenorphin [PDF]

, 2018
C. Vidal, W. R. Külpmann
openaire   +1 more source

Buprenorphine Treatment Divide by Race/Ethnicity and Payment.

JAMA psychiatry, 2019
Pooja Lagisetty, Ryan D. Ross, A. Bohnert, Michael Clay, D. Maust   +4 more
semanticscholar   +1 more source

Among people who use heroin, tobacco smoking and illegal drugs cause a similar number of premature deaths

Addiction, EarlyView.
Abstract Background and aims Most people who use heroin also smoke tobacco, but there is limited investment to reduce the prevalence of smoking in this group. This may be due to a perception that tobacco is less harmful than other substances and is a lower priority problem. Among people who use heroin in England, we aimed to compare tobacco smoking and
Dan Lewer, Harry Tattan‐Birch, Sharon Cox   +2 more
wiley   +1 more source

Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population‐based target trial in British Columbia, Canada

Addiction, EarlyView.
Abstract Background and aim Urine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self‐reported substance use, monitoring for diversion and supporting clinical decisions for take‐home dosing. However, there is a paucity of evidence to support the practice of urine drug testing.
Megan Kurz, Brenda Carolina Guerra‐Alejos, Jeong Eun Min, Shaun R. Seaman, Micah Piske, Paxton Bach, Julie Bruneau, Sander Greenland, Paul Gustafson, Kyle Kampman, Mohammad Ehsanul Karim, P. Todd Korthuis, Robert W. Platt, Uwe Siebert, M. Eugenia Socías, Evan Wood, Bohdan Nosyk   +16 more
wiley   +1 more source

Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl

Addiction Science & Clinical Practice
Background In response to greater illicit fentanyl use, buprenorphine daily doses exceeding the FDA’s recommended target daily dose (16 mg) and maximum suggested daily dose (24 mg) may provide better outcomes, but little is known about higher dosage ...
Bradley D. Stein, Flora Sheng, Brendan K. Saloner, Adam J. Gordon, Jessica S. Merlin   +4 more
doaj   +1 more source

Pharmacological properties of buprenorphine, a new analgesic agent. Part II

, 1982
S Shintani, Masanao UMEZATO, Yoshifumi TOBA, Yoshiaki Yamaji, Keisuke Kitaura, Takeshi Tani, H. Ishiyama, Tetsuro Kikuchi, Toyoki Mori, Satoru Nakai, K Watanabe, Takashi Hiyama   +11 more
openalex   +2 more sources

The effects of buprenorphine, nalbuphine and butorphanol alone or following halothane anaesthesia on food and water consumption and locomotor movement in rats [PDF]

, 1992
J. H. Liles, Paul Flecknell
openalex   +1 more source

Counterfeit ‘Xanax®’ tablets: A comparative study of clinical and seizure data in Victoria, Australia

Addiction, EarlyView.
Abstract Background and aim There is growing evidence of counterfeit benzodiazepine products containing other substances, including non‐regulated benzodiazepine‐type new psychoactive substances (NPSs). This study sought to compare detections of seized suspect counterfeit alprazolam products with clinical cases that reported use of an alprazolam ...
Rebekka Syrjanen, Shaun L. Greene, Sarah E. Hodgson, Rachelle Abouchedid, Dimitri Gerostamoulos, Christie Magee, Melissa Bremner, Jennifer L. Schumann, on behalf of the Emerging Drugs Network of Australia – Victoria (EDNAV) research group   +8 more
wiley   +1 more source

Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain

Journal of Pain Research, 2015
Ish K Khanna, Sivaram PillarisettiNeuroPn Therapeutics, Alpharetta, GA, USAAbstract: Despite proven clinical utility, buprenorphine has not been used widely for the treatment of chronic pain.
Khanna IK, Pillarisetti S
doaj